STOK — Stoke Therapeutics Share Price
0.000.00%
Last trade - 00:00- $620.26m
- $418.87m
- $8.78m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.89 | ||
| Price to Tang. Book | 3.89 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 70.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -58.11% | ||
| Return on Equity | -60.8% | ||
| Operating Margin | -1307.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 12.4 | 8.78 | 12.33 | 15.73 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Directors
- Seth Harrison NEC (60)
- Edward Kaye CEO (72)
- Stephen Tulipano CFO (61)
- Huw Nash COO (54)
- Gene Liau CSO (66)
- Barry Ticho OTH (61)
- Jennifer Burstein IND (49)
- Adrian Krainer IND (62)
- Arthur Levin IND (67)
- Garry Menzel IND (57)
- Julie Smith IND (50)
- Arthur Tzianabos IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 13th, 2014
- Public Since
- June 19th, 2019
- No. of Shareholders
- 6
- No. of Employees
- 110
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 51,473,790
- Address
- 45 WIGGINS AVENUE, BEDFORD, 01730
- Web
- https://www.stoketherapeutics.com/
- Phone
- +1 7814308200
- Contact
- Eric Rojas
- Auditors
- KPMG LLP
Upcoming Events for STOK
Stoke Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Stoke Therapeutics Inc Earnings Release
Similar to STOK
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Stoke Therapeutics share price?
As of Today at 19:20 UTC, shares in Stoke Therapeutics are trading at $12.05. This share price information is delayed by 15 minutes.
How has the Stoke Therapeutics share price performed this year?
Shares in Stoke Therapeutics last closed at $12.05 and the price had moved by +41.6% over the past 365 days. In terms of relative price strength the Stoke Therapeutics share price has outperformed the S&P500 Index by +17.83% over the past year.
What are the analyst and broker recommendations for Stoke Therapeutics?
The overall consensus recommendation for Stoke Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Stoke Therapeutics dividend yield?
Stoke Therapeutics does not currently pay a dividend.
Does Stoke Therapeutics pay a dividend?
Stoke Therapeutics does not currently pay a dividend.
When does Stoke Therapeutics next pay dividends?
Stoke Therapeutics does not currently pay a dividend.
How do I buy Stoke Therapeutics shares?
To buy shares in Stoke Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Stoke Therapeutics?
As of the previous close price of $12.05, shares in Stoke Therapeutics had a market capitalisation of $620.26m.
Where are Stoke Therapeutics shares listed?
Here are the trading details for Stoke Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: STOK
What kind of share is Stoke Therapeutics?
Based on an overall assessment of its quality, value and momentum Stoke Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Stoke Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Stoke Therapeutics is $23.67. That is 96.43% above the last closing price of $12.05.
Analysts covering Stoke Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.31 for the next financial year.
What is the trend in the Stoke Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Stoke Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +174.27%.
As of the last closing price of $12.05, shares in Stoke Therapeutics were trading +97.35% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Stoke Therapeutics PE Ratio?
The Stoke Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $12.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Stoke Therapeutics?
Stoke Therapeutics' management team is headed by:
- Seth Harrison - NEC
- Edward Kaye - CEO
- Stephen Tulipano - CFO
- Huw Nash - COO
- Gene Liau - CSO
- Barry Ticho - OTH
- Jennifer Burstein - IND
- Adrian Krainer - IND
- Arthur Levin - IND
- Garry Menzel - IND
- Julie Smith - IND
- Arthur Tzianabos - IND